A leading Norwegian oncology arena
Cancer Crosslinks 2023 attracted more than 300 on-site participants.
If you are not happy with the results below please do another search
Cancer Crosslinks 2023 attracted more than 300 on-site participants.
Cancer Crosslinks 2023 will feature a number of renowned cancer researchers from across the globe.
Update from Targovax on melanoma study shows responses in 7 of 20 patients.
BerGenBio is testing the company’s cancer medicine as a treatment for Covid-19.
Targovax releases 12-month data from clinical trial
We want to accelerate cancer research in T cell immunotherapy!
We are happy to welcome three new members to the board of Oslo Cancer Cluster. Find out what they had to say about entering their new positions.
During Cancer Crosslinks 2019 one thing was crystal clear: there is a need to include broader genomic testing into treatments for cancer patients in Norway.